BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17616534)

  • 21. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients.
    Wang D; Wu WZ; Chen JH; Yang SL; Wang QH; Zeng ZX; Tan JM
    Transpl Immunol; 2010 Feb; 22(3-4):115-20. PubMed ID: 20036333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serial soluble CD30 measurements as a predictor of kidney graft outcome.
    Halim MA; Al-Otaibi T; Al-Muzairai I; Mansour M; Tawab KA; Awadain WH; Balaha MA; Said T; Nair P; Nampoory MR
    Transplant Proc; 2010 Apr; 42(3):801-3. PubMed ID: 20430176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation.
    Heinemann FM; Rebmann V; Witzke O; Philipp T; Broelsch CE; Grosse-Wilde H
    Transplantation; 2007 Mar; 83(6):706-11. PubMed ID: 17414702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
    Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
    Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes.
    Yang JL; Hao HJ; Zhang B; Liu YX; Chen S; Na YQ
    Transplant Proc; 2008 Dec; 40(10):3381-3. PubMed ID: 19100394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection.
    Kim KH; Oh EJ; Jung ES; Park YJ; Choi JY; Kim DG; Lee KY; Kang CS
    Transplant Proc; 2006 Jun; 38(5):1429-31. PubMed ID: 16797323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation.
    Hamer R; Roche L; Smillie D; Harmer A; Mitchell D; Molostvov G; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Briggs D; Lowe D; Zehnder D; Higgins R
    Transpl Immunol; 2010 Aug; 23(4):161-5. PubMed ID: 20600903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-transplant monitoring of soluble CD30 level as predictor of graft outcome: a single center experience from China.
    Wang D; Wu W; Yang S; Wang Q; Tan J
    Transpl Immunol; 2012 Dec; 27(4):146-50. PubMed ID: 23079227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols.
    Hire K; Hering B; Bansal-Pakala P
    Transpl Immunol; 2010 Aug; 23(4):209-14. PubMed ID: 20600901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
    Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation.
    Nikaein A; Spiridon C; Hunt J; Rosenthal J; Anderson A; Eichhorn E; Magee M; Dewey T; Mack M
    Clin Transplant; 2007; 21(6):744-7. PubMed ID: 17988268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
    Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
    Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
    Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P; Pretagostini R; Arpino A; Tamburro ML; Mengasini S; Lattanzi R; De Simone P; Berloco P; Molajoni ER
    Transplantation; 2005 May; 79(9):1154-6. PubMed ID: 15880060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S; Polakowska E
    Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.
    Langan LL; D'Orsogna L; Park LP; Hughes TL; Irish A; Luxton G; Witt CS; Christiansen FT
    Clin Transpl; 2006; ():219-25. PubMed ID: 18365380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P; Pretagostini R; Arpino A; Tamburro ML; Mengasini S; Lattanzi R; De Simone P; Berloco P; Molajoni ER
    Transplantation; 2005 Mar; 79(5):599-601. PubMed ID: 15753850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft.
    Slavcev A; Honsova E; Lodererova A; Pavlova Y; Sajdlova H; Vitko S; Skibova J; Striz I; Viklicky O
    Transpl Immunol; 2007 Jul; 18(1):22-7. PubMed ID: 17584598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
    Vaidya S; Partlow D; Barnes T; Thomas P; Gugliuzza K
    Clin Transplant; 2006; 20(4):461-4. PubMed ID: 16842522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.